![]() |
|
|
,**,
,
,¶
*
Department of Nutrition, Harvard School of Public Health,
Division of Hematology/Oncology, Childrens Hospital,
**
Division of Hematology, Brigham & Womens Hospital, and Departments of
Medicine and
Pediatrics, Harvard Medical School,
¶
Howard Hughes Medical Institute, Boston, Massachusetts 02115
3To whom correspondence should be addressed at Harvard School of Public Health, Department of Nutrition, Bldg. 2, Room 205, 665 Huntington Avenue, Boston, MA 02115. E-mail: wessling{at}hsph.harvard.edu
Hfe knockout (-/-) mice recapitulate many of the biochemical abnormalities of hereditary hemochromatosis (HH), but the molecular mechanisms involved in the etiology of iron overload in HH remain poorly understood. It was found previously that livers of patients with HH contained 5-fold higher SFT (stimulator of Fe transport) mRNA levels relative to subjects without HH. Because this observation suggests a possible role for SFT in HH, we investigated SFT mRNA expression in Hfe-/- mice. The 4- and 10-wk-old Hfe-/- mice do not have elevated levels of hepatic SFT transcripts relative to age-matched Hfe+/+ mice, despite having 2.2- and 3.3-fold greater hepatic nonheme iron concentrations, respectively. Northern blot analyses of various mouse tissues revealed that SFT is widely expressed. The novel observation that SFT transcripts are abundant in brain prompted a comparison of SFT transcript levels and nonheme iron levels in the brains of Hfe+/+ and Hfe-/- mice. Neither SFT mRNA levels nor nonheme iron levels differed between groups. Further comparisons of Hfe-/- and Hfe+/+ mouse tissues revealed no significant differences in SFT mRNA levels in duodenum, the site of increased iron absorption in HH. Important distinctions between Hfe-/- mice and HH patients include not only differences in the relative rate and magnitude of iron loading but also the lack of fibrosis and phlebotomy treatment in the knockout animals.
KEY WORDS: stimulator of Fe transport HFE hemochromatosis brain mice
This article has been cited by other articles:
![]() |
T. MOOS and E. H. MORGAN The Metabolism of Neuronal Iron and Its Pathogenic Role in Neurological Disease: Review Ann. N.Y. Acad. Sci., March 1, 2004; 1012(1): 14 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Knutson, M. R. Vafa, D. J. Haile, and M. Wessling-Resnick Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages Blood, December 1, 2003; 102(12): 4191 - 4197. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yang, K. Mori, J. Y. Li, and J. Barasch Iron, lipocalin, and kidney epithelia Am J Physiol Renal Physiol, July 1, 2003; 285(1): F9 - F18. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Gehrke, H.-D. Riedel, T. Herrmann, B. Hadaschik, K. Bents, C. Veltkamp, and W. Stremmel UbcH5A, a member of human E2 ubiquitin-conjugating enzymes, is closely related to SFT, a stimulator of iron transport, and is up-regulated in hereditary hemochromatosis Blood, April 15, 2003; 101(8): 3288 - 3293. [Abstract] [Full Text] [PDF] |
||||